Zhao-Kui Wan

USPTO Granted Patents = 16 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 8.5

ph-index = 3

Forward Citations = 48(Granted Patents)

Location History:

Arlington, MA (US) (2009 - 2010)
Lexington, MA (US) (2017 - 2023)
Shanghai, CN (2020 - 2023)

Company Filing History:

Janssen Pharmaceutica Nv

Janssen Sciences Ireland Unlimited Company

patents

Years Active: 2009-2023

Loading Chart...

16 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11691970 - Pyrazolopyridinone compounds (2023-07-04),

2. 11639350 - Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections (2023-05-02),

3. 11396517 - Exo-aza spiro inhibitors of menin-MLL interaction (2022-07-26),

4. 11384099 - Pyrazolopyridinone compounds (2022-07-12),

5. 11384075 - Quinolinone compounds (2022-07-12),

6. 11197867 - Aminopyrimidinyl compounds (2021-12-14),

7. 11053235 - Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases (2021-07-06),

8. 10980815 - Aminopyrimidinyl compounds (2021-04-20),

9. 10815213 - Bruton's tyrosine kinase inhibitors (2020-10-27),

10. 10654837 - Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis (2020-05-19),

11. 10463675 - Aminopyrimidinyl compounds (2019-11-05),

12. 10266513 - Bruton's tyrosine kinase inhibitors (2019-04-23),

13. 9663526 - Aminopyrimidinyl compounds (2017-05-30),

14. 7674822 - PTP1b inhibitors (2010-03-09),

15. 7632838 - 11-beta HSD1 inhibitors (2009-12-15),

Title: Innovations and Contributions of Inventor Zhao-Kui Wan

Introduction

Zhao-Kui Wan is a prominent inventor based in Lexington, MA, known for his significant contributions to the field of pharmaceuticals. With a total of 16 patents to his name, he has made remarkable advancements in the development of compounds that target critical health issues, including cancer and hepatitis B infections.

Latest Patents

Among his latest patents, Zhao-Kui Wan has developed pyrazolopyridinone compounds, which are pharmaceutical compositions that serve as fibroblast growth factor receptor (FGFR) inhibitors. These compounds are particularly valuable in the treatment of various diseases, including cancer. Additionally, he has worked on heteroaryldihydropyrimidine derivatives, which are designed to treat hepatitis B infections. These compounds provide methods for inhibiting, suppressing, or preventing HBV infection in subjects, showcasing his innovative approach to tackling viral diseases.

Career Highlights

Zhao-Kui Wan has had a distinguished career, having worked with leading pharmaceutical companies such as Pfizer Corporation and Janssen Pharmaceutica NV. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Throughout his career, Zhao-Kui Wan has collaborated with notable professionals in the field, including Eddine Saiah and Li Huang Xing. These partnerships have further enhanced his research capabilities and have led to significant advancements in his areas of expertise.

Conclusion

Zhao-Kui Wan's innovative work in the pharmaceutical sector has led to the development of crucial compounds that address serious health challenges. His contributions continue to impact the field positively, demonstrating the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.